Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 65, Issue 6, 2013, Pages 1592-1602

  Isgro, Josephine ^a   Gupta, Sanjay ^b   Jacek, Elzbieta ^b   Pavri, Tanya ^b   Duculan, Roland ^b   Kim, Mimi ^c   Kirou, Kyriakos A ^a   Salmon, Jane E ^b   Pernis, Alessandra B ^b  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHEMOKINE; CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 21; RHO KINASE;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL LYSATE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TH0 CELL; TH17 CELL; UMBILICAL CORD BLOOD;

ADOLESCENT; ADULT; AGED; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CROSS-SECTIONAL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RHO-ASSOCIATED KINASES; TH17 CELLS; YOUNG ADULT;

EID: 84878579250     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37934     Document Type: Article

References (48)

1. Ridley AJ,. Rho family proteins: coordinating cell responses. Trends Cell Biol 2001; 11: 471-7. (Pubitemid 33079138)
2. Guilluy C, Garcia-Mata R, Burridge K,. Rho protein crosstalk: another social network? Trends Cell Biol 2011; 21: 718-26.
3. Noma K, Oyama N, Liao JK,. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006; 290: C661-8.
4. Wettschureck N, Offermanns S,. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med (Berl) 2002; 80: 629-38. (Pubitemid 35471727)
5. Zhou Q, Gensch C, Liao JK,. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 2011; 32: 167-73.
6. Satoh K, Fukumoto Y, Shimokawa H,. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 2011; 301: H287-96.
7. Surma M, Wei L, Shi J,. Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol 2011; 7: 657-71.
8. Hayashi K, Wakino S, Kanda T, Homma K, Sugano N, Saruta T,. Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury. J Pharmacol Sci 2006; 100: 29-33. (Pubitemid 43161611)
9. Komers R,. Rho kinase inhibition in diabetic nephropathy. Curr Opin Nephrol Hypertens 2011; 20: 77-83.
10. Kubo T, Yamaguchi A, Iwata N, Yamashita T,. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther Clin Risk Manag 2008; 4: 605-15. (Pubitemid 352037900)
11. Wang QM, Liao JK,. ROCKs as immunomodulators of stroke. Expert Opin Ther Targets 2012; 16: 1013-25.
12. Shimokawa H, Takeshita A,. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-75. (Pubitemid 41243442)
13. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 2002; 40: 751-61. (Pubitemid 36109293)
14. Vicari RM, Chaitman B, Keefe D, Smith WB, Chrysant SG, Tonkon MJ, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005; 46: 1803-11. (Pubitemid 41579800)
15. Zhou Q, Liao JK,. Pleiotropic effects of statins: basic research and clinical perspectives. Circ J 2010; 74: 818-26.
16. Li Y, Harada T, Juang YT, Kyttaris VC, Wang Y, Zidanic M, et al. Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J Immunol 2007; 178: 1938-47. (Pubitemid 46154667)
17. Biswas PS, Gupta S, Chang E, Song L, Stirzaker RA, Liao JK, et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest 2010; 120: 3280-95.
18. Garrett-Sinha LA, John S, Gaffen SL,. IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol 2008; 20: 519-25.
19. Apostolidis SA, Lieberman LA, Kis-Toth K, Crispin JC, Tsokos GC,. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res 2011; 31: 769-79.
20. Pernis AB,. Th17 cells in rheumatoid arthritis and systemic lupus erythematosus. J Intern Med 2009; 265: 644-52.
21. Stirzaker RA, Biswas PS, Gupta S, Song L, Bhagat G, Pernis AB,. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. Lupus 2012; 21: 656-61.
22. Liu PY, Liao JK,. A method for measuring Rho kinase activity in tissues and cells. Methods Enzymol 2008; 439: 181-9.
23. Gupta S, Xia D, Jiang M, Lee S, Pernis AB,. Signaling pathways mediated by the TNF- and cytokine-receptor families target a common cis-element of the IFN regulatory factor 1 promoter. J Immunol 1998; 161: 5997-6004. (Pubitemid 28535968)
24. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
25. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al, for the OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. New Engl J Med 2005; 353: 2550-8. (Pubitemid 41785892)
26. Hua J, Kirou K, Lee C, Crow MK,. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006; 54: 1906-16. (Pubitemid 43877940)
27. Wan W, Murphy PM,. Regulation of atherogenesis by chemokine receptor CCR6. Trends Cardiovasc Med 2011; 21: 140-4.
28. Comerford I, Bunting M, Fenix K, Haylock-Jacobs S, Litchfield W, Harata-Lee Y, et al. An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation? CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. Bioessays 2010; 32: 1067-76.
29. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-86. (Pubitemid 37531913)
30. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10. (Pubitemid 32038409)
31. Cheema GS, Roschke V, Hilbert DM, Stohl W,. Elevated serum B lymphocyte stimulator levels in patients with systemic immune- based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-9. (Pubitemid 32537529)
32. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453-9.
33. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al, for the BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-30.
34. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31.
35. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK,. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007; 8: 492-502. (Pubitemid 47365615)
36. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL,. Immune interferon in the circulation of patients with autoimmune disease. New Engl J Med 1979; 301: 5-8. (Pubitemid 9226519)
37. Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL, et al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 2011; 63: 1044-53.
38. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK,. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-503. (Pubitemid 40663941)
39. Kariuki SN, Franek BS, Kumar AA, Arrington J, Mikolaitis RA, Utset TO, et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther 2010; 12: R151.
40. + T cells derived from patients with multiple sclerosis. J Immunol 2011; 187: 3431-7.
41. Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1472-83.
42. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW,. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008; 127: 385-93.
43. Zhao XF, Pan HF, Yuan H, Zhang WH, Li XP, Wang GH, et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2010; 37: 81-5.
44. Shah K, Lee WW, Lee SH, Kim SH, Kang SW, Craft J, et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 2010; 12: R53.
45. Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006; 176: 640-51. (Pubitemid 43023313)
46. + T cells. Autoimmun Rev 2009; 8: 199-203.
47. Skaggs BJ, Hahn BH, McMahon M,. Accelerated atherosclerosis in patients with SLE-mechanisms and management. Nat Rev Rheumatol 2012; 8: 214-23.
48. Salmon JE, Roman MJ,. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008; 121: S3-8.